Robert W Baird
-
Baird Reiterates an 'Outperform' on Endocyte (ECYT); Remains Top Small-Cap Pick
-
Baird Starts Endocyte (ECYT) at Outperform, Sees 100% Upside
-
Endocyte (ECYT) Prices IPO at $6
